🏅 FDA Orphan Designation
PROCYSBI
cysteamine enteric coated
Manufacturer: Horizon Therapeutics USA, Inc.
Indicated for:
Ocular cystinosisOrphan
FDA-Approved Indications (1)
Ocular cystinosisOrphan Designation
PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
Indications & Usage
1 INDICATIONS AND USAGE PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older. PROCYSBI is a cystine-depleting agent indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older. ( 1 )
💙 Support Programs
View all →PROCYSBI
Horizon Therapeutics USA, Inc.
PROCYSBI
Amgen
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.